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Background/aim: The aim of this study was to determine the usefulness of tigecycline in combination treatment of Stenotrophomonas
maltophilia infections by evaluating the in vitro synergistic effects of tigecycline with various antibiotics using the E-test method.
Materials and methods: Synergy testing by E-test was performed with various antibiotic combinations in 10 S. maltophilia isolates
identified as a cause of infection. The antibiotics used in the study included tigecycline (TGC), cefoperazone-sulbactam (CPS),
ceftazidime (TZ), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (cotrimoxazole) (TS). Four different combinations (TGCCPS, TGC-TZ, TGC-LEV, TGC-TS) were studied with the E-test synergy method.
Results: S. maltophilia isolates were found to have the highest level of susceptibility to trimethoprim-sulfamethoxazole, tigecycline, and
levofloxacin. The fractional inhibitory concentration (FIC) index was calculated as FIC = MICAB/MICA + MICBA/MICB. The FIC
index values were calculated and classified as synergistic (FIC < 0.5), additive (FIC = 0.5–1), indifferent (FIC = 1–4), and antagonistic
(FIC > 4). According to FIC index values, synergy was found with the highest rate with TGC-CPS and TGC-LEV combinations (20%).
Antagonistic activity was not found in any combination.
Conclusion: When trimethoprim-sulfamethoxazole cannot be used because of resistance or allergy, tigecycline alone or in combination
may be included as an alternative option. Although in vitro results are promising, clinical data are required.
Key words: Combination, Stenotrophomonas maltophilia, synergy, tigecycline

1. Introduction
Stenotrophomonas maltophilia is a nonfermentative
bacterium that studies over the last 10 years have shown
to be a significant nosocomial pathogen. The most
common nosocomial infections caused by S. maltophilia
are bacteremia and pneumonia, which frequently lead to
complications and death (1,2). Studies have shown that
the mortality rate of S. maltophilia infections increased
up to 37.5% in patients who received inappropriate
antibiotic treatment as compared to patients who received
appropriate antibiotic treatment (3). S. maltophilia
is intrinsically resistant to β-lactams, quinolones,
aminoglycosides, tetracyclines, and disinfectants (4,5).
There is no ideal standard treatment. The agent that is
used most commonly in treatment is cotrimoxazole
(6,7), but it may be contraindicated in cases for causing
allergic reaction. There are also reports of cotrimoxazole
resistance among S. maltophilia isolates that acquired the
sul gene (8). Levofloxacin is an alternative drug option for
treatment of S. maltophilia infections (susceptibility rates:

78%–87%) (9,10), but there are reports of fluoroquinolone
resistance caused by membrane proteins and efflux pumps
(5,7). Because of the potential for resistance development,
some authors recommend antibiotic combinations for S.
maltophilia infection treatment (11).
Tigecycline is the first antibiotic in the glycylcycline
group. Tigecycline is approved to treat complicated skin
and soft tissue infections, complicated intraabdominal
infections, and community-acquired pneumonia. It shows
therapeutic activity against gram-positive and gramnegative microorganisms, including those with multidrug
resistance (12). In vitro susceptibility rates of tigecycline
were found to be high, above 90%, in many studies
worldwide (13).
In this study, we aimed to determine the usefulness
of tigecycline in combination treatment of S. maltophilia
infections by evaluating the in vitro effects of combinations
of tigecycline with various antibiotics. We used the
E-test method for 10 S. maltophilia isolates identified as
infectious agents.
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2. Materials and methods
The E-test synergy method was performed using various
antibiotic combinations and 10 S. maltophilia isolates
identified as causative agents. The isolates used in this
study were selected from S. maltophilia isolates causing
nosocomial infection in various services and intensive care
units at the Gazi University Hospital between January 2011
and June 2015. The distribution of the clinical specimens
of the isolates were as follows: peripheral blood culture 4
(40%), catheter blood culture 2 (20%), ETA (endotracheal
aspirate) culture 2 (20%), pleural fluid culture 1 (10%), and
bile fluid culture 1 (10%).
2.1. In vitro E-test synergy method
The isolates obtained in our study were stored at –80 °C
until the study was performed. The isolates were identified
using a BBL Crystal Enteric/Nonfermenter ID Kit (Becton
Dickinson, USA).
The minimum inhibitory concentration (MIC) values
of tigecycline, cotrimoxazole, levofloxacin, ceftazidime,
and cefoperazone-sulbactam were determined using the
E-test method. For the E-test, suspensions equivalent
to 0.5 McFarland standard were obtained from pure
bacterial colonies and inoculated onto Mueller–Hinton
medium (Becton Dickinson). E-test strips were prepared
for each antibiotic. After incubation for 24 h at 35
°C, MICs were read and interpreted according to the
manufacturer’s instructions. To prevent misinterpretation
of tigecycline MICs, the agar plates were used within
12 h after preparation. The susceptibility breakpoints
for cotrimoxazole, levofloxacin, and ceftazidime were
interpreted using the Clinical Laboratory Standard
Institute’s criteria for S. maltophilia. The cefoperazonesulbactam susceptibility was determined by the CLSI
criteria for Enterobacteriaceae (14). Tigecycline
susceptibility was determined using the Food and Drug
Administration’s breakpoints for Enterobacteriaceae (15).

For the synergy method, the E-test strip of drug A
was applied to the surface of agar plates and left for 1 h
at room temperature. Subsequently, the strip was removed
and a strip of drug B was applied onto the imprint of
strip A. The plates were incubated for 24 h at 35 °C and
then the MIC levels of each drug and combination were
read. The fractional inhibitor concentration (FIC) index
was calculated using the formula FIC = MICAB/MICA +
MICBA/MICB. The FIC index was interpreted as follows:
synergistic, ≤0.5, additive, >0.5 to <1, indifferent, >1 to ≤4,
and antagonistic, >4.
Pseudomonas aeruginosa ATCC (American Type
Culture Collection) 27853 and Escherichia coli ATCC
25922 were used as quality control strains.
3. Results
The MIC values of the antibiotics among S. maltophilia
isolates are shown in Table 1. The susceptibilities of
the antibiotics were as follows: cotrimoxazole (100%),
tigecycline (80%), levofloxacin (80%), ceftazidime (70%),
and cefoperazone-sulbactam (50%).
In vitro interactions (synergic, additive, indifferent, and
antagonistic) of the 4 combinations studied (TGC-CPS,
TGC-TZ, TGC-LEV, TGC-TS) according to FIC results
are shown in Table 2. Synergy was found with the highest
rate in TGC-CPS and TGC-LEV combinations (20%) and
antagonistic activity was not found in any combination.
4. Discussion
S. maltophilia has a high level of intrinsic resistance to
β-lactams, quinolones, aminoglycosides, tetracyclines,
disinfectants, and heavy metals. Management of these
infections is difficult because of resistance to many
antimicrobial agents. The therapeutic agent recommended
for S. maltophilia is cotrimoxazole. Some recent studies
have instead recommended antimicrobial combination

Table 1. MIC values of the isolates.

1st isolate

TGC (D: ≤2 µm/mL) CPS (D: ≤16 µm/mL)

TS (D: ≤2/38 µm/mL) TZ (D: ≤8 µm/mL) LEV (D: ≤2 µm/mL)

0.75

0.25

64

256

0.5

2nd isolate

0.38

64

0.064

256

0.25

3rd isolate

0.5

48

0.047

4

0.5

4th isolate

1

16

0.038

8

0.5

5th isolate

4

6

0.047

1

4

6th isolate

0.38

16

0.125

8

0.5

7th isolate

4

96

0.064

256

8

8th isolate

0.5

4

0.032

3

0.5

9th isolate

0.25

48

0.032

3

0.25

10th isolate

2

3

0.125

0.75

0.25

TGC: Tigecycline, TS: Trimethoprim-sulfamethoxazole, LEV: levofloxacin CPS: cefoperazone-sulbactam, TZ: ceftazidime.
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Table 2. The results of in vitro interactions of 4 antibiotic combinations.
Antibiotic combinations Synergic number (%) Additive number (%) Indifferent number (%) Antagonist number (%)
TGC-CPS
TGC-TZ
TGC-LEV
TGC-TS

2 (20)
1 (10)
2 (20)
0 (0)

4 (40)
5 (50)
7 (70)
8 (80)

4 (40)
4 (40)
1 (10)
2 (20)

0 (0)
0 (0)
0 (0)
0 (0)

TGC: Tigecycline, TS: trimethoprim-sulfamethoxazole, LEV: levofloxacin, CPS: cefoperazone-sulbactam, TZ: ceftazidime.

therapies, especially for patients with septic shock or
neutropenia, immunocompromised patients, and patients
intolerant of cotrimoxazole, but only a few studies have
been focused on these antibiotic combinations (16).
Zelenitsky et al. conducted a study comparing
cotrimoxazole monotherapy and its combinations
with various antibiotics (ciprofloxacin, ceftazidime,
gentamycin, and tobramycin) in 4 clinical isolates in an
in vitro pharmacodynamic infection model. They found
that cotrimoxazole worked as a bacteriostatic agent
against all isolates when given alone, and all combinations
of cotrimoxazole were more active than monotherapy
as determined by bacterial reductions at both 24 and 48
h. They concluded that their preclinical data supported
further investigation of antibiotic combinations in the
treatment of serious S. maltophilia infections (17).
In clinical S. maltophilia isolates, tetracycline
derivatives minocycline, doxycycline, and tigecycline
have been shown to have high in vitro efficacy. There is
a very little evidence of their use in treatment, however
(6). Tigecycline, a wide-spectrum glycylcycline derivative,
may overcome tetracycline resistance related to efflux
pumps and ribosomal target modification. Studies have
found that tigecycline is effective for strains resistant to
cotrimoxazole (18,19). In a global study evaluating 1586
isolates, the susceptibility rates were 96% for cotrimoxazole
and 95.5% for tigecycline (13). In a study conducted
by Church et al., 17% of the S. maltophilia isolates were
resistant to cotrimoxazole. Minocycline, tigecycline, and
colistin had the highest efficacy. Colistin and tigecycline
combination produced the best results (20). In another
study conducted by Wei et al., synergism and antagonism
were not detected in tigecycline + cotrimoxazole and

tigecycline + ceftazidime combinations. All of the isolates
showed indifferent activity. While synergy was found
in a few isolates in the tigecycline and moxifloxacin
combination, antagonistic action was not detected in any
combination (21).
According to the results of in vitro studies, tigecycline
could be considered an alternative option in the treatment
of S. maltophilia infections, especially in combination
therapy (22). However, the choice between monotherapy
and combination therapy remains controversial. In a
study performed by Tekce et al., the efficacy of tigecycline
treatment was compared with cotrimoxazole in nosocomial
S. maltophilia infections over a 3-year period. Clinical
improvement was similar in the two groups: 69.2% in the
cotrimoxazole group and 68.4% in the tigecycline group.
The authors concluded that tigecycline can be considered
as an alternative option in the treatment of S. maltophilia
infections (23). Apart from this study, anecdotal evidence
about the use of tigecycline in treatment has been reported
in some studies. There are no data about the use of this
agent in combination in clinical practice (24–26).
In our study, cotrimoxazole showed the lowest
MIC levels against S. maltophilia isolates, followed by
levofloxacin and tigecycline. We also evaluated tigecycline
in combination with 4 different antibiotics. The best
results were obtained with TGC + CPS and TGC + LEV
combinations. Additive interaction was detected mainly
in the TGC + CPS combination. In vitro synergy studies
do not show the effects of antibiotic pharmacodynamics
and host immune response, but synergistic combinations
(TGC + CPS and TGC + LEV) may still be a therapeutic
option in certain S. maltophilia infections. Our results
should be supported with clinical studies.
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